Regencell Bioscience Holdings, a Hong Kong-based early-stage biotech focused on traditional Chinese medicine for neurocognitive disorders, experienced extraordinary stock volatility in 2025. Shares skyrocketed over 64,000% after a 38-for-1 stock split triggered speculative retail buying and short squeeze dynamics, surging from about $0.10 to an $83.60 peak market cap of $33 billion despite lacking FDA approvals or revenue. Regulatory trading halts followed, and shares subsequently plunged 74% but remain significantly above year-start levels. The episode mirrors meme-stock phenomena driven by investor mania rather than fundamentals.